Haemato AG engages in the pharmaceutical industry. It focuses on growth markets of patent-free, and patented medicinal products in the insurance-financed market. Its portfolio include therapies for cancer, HIV, rheumatology, and other chronic diseases, and products for the privately financed market for aesthetic treatments. It operates through the Lifestyle and Aesthetics, and Specially Pharma segments. The company was founded on May 10, 1993 and is headquartered in Schönefeld, Germany.
M1 Kliniken AG: HAEMATO AG prüft Angebot für den Verkauf ihres Handelssegments^EQS-Ad-hoc: M1 Kliniken AG / Schlagwort(e):Beteiligung/Unternehmensbeteiligung/SonstigesM1...
Die HAEMATO Aktie verzeichnete am 16. März 2025 einen weiteren Kursrückgang und schloss bei 11,08 EUR, was einem Minus von 0,23% zum Vortag entspricht. Der Pharmawertpapier-Titel...
